A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

CNS Drugs · 2018 · PMC5889769 · PMID 29557078

Europe PMC DOI

hedged sentences

0.0280

closest p · 0.6× alpha

0.0280

boldest claim

The sentences

highly significantp = 0.028actually significant

Treatment and visit were both highly significant, and a treatment-by-visit interaction ( p = 0.028) was present indicating improvement over time in the mazindol CR group but not in the placebo group.

also in 132,142 other papers

showed a trendno p-value reported

Subjects receiving mazindol CR showed a trend of decreasing body weight as early as Day 7, and by Day 42 there was a mean weight loss for the mazindol CR group (− 1.73 kg; range − 9.6 to + 3.7) and a mean weight gain for the placebo group (1.07 kg; range − 2.0 to + 11.0).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.